Molecular insights into the role of AMPA receptors in the synaptic plasticity, pathogenesis and treatment of epilepsy: therapeutic potentials of perampanel and antisense oligonucleotide (ASO) technology.

Acta neurologica Belgica
Saeid CharsoueiAmin Karimi-Moghadam

Abstract

Glutamate is considered as the predominant excitatory neurotransmitter in the mammalian central nervous systems (CNS). Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are the main glutamate-gated ionotropic channels that mediate the majority of fast synaptic excitation in the brain. AMPARs are highly dynamic that constitutively move into and out of the postsynaptic membrane. Changes in the postsynaptic number of AMPARs play a key role in controlling synaptic plasticity and also brain functions such as memory formation and forgetting development. Impairments in the regulation of AMPAR function, trafficking, and signaling pathway may also contribute to neuronal hyperexcitability and epileptogenesis process, which offers AMPAR as a potential target for epilepsy therapy. Over the last decade, various types of AMPAR antagonists such as perampanel and talampanel have been developed to treat epilepsy, but they usually show limited efficacy at low doses and produce unwanted cognitive and motor side effects when administered at higher doses. In the present article, the latest findings in the field of molecular mechanisms controlling AMPAR biology, as well as the role of these mechanism dysfunctions in generat...Continue Reading

References

Jan 1, 1994·Annual Review of Neuroscience·M Hollmann, S Heinemann
Jan 7, 1993·Nature·T V Bliss, G L Collingridge
Feb 28, 2002·The European Journal of Neuroscience·Klaus KrampflJohannes Bufler
Apr 5, 2002·Neuron·Jonathan G HanleyEdward B Ziff
Aug 15, 2002·Learning & Memory·Eric Klann
Oct 24, 2002·Trends in Neurosciences·Insuk Song, Richard L Huganir
May 15, 2003·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·R G M MorrisC O'Carroll
Jul 10, 2003·Current Opinion in Neurobiology·Peter H Seeburg, Jochen Hartner
Feb 21, 2004·Nature Reviews. Neuroscience·Gareth M Thomas, Richard L Huganir
Jun 15, 2004·Current Opinion in Neurobiology·J David Sweatt
Aug 13, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Miho TerunumaMasato Hirata
Sep 29, 2004·Neuron·Robert C Malenka, Mark F Bear
Nov 5, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Iskander IsmailovMichael J Friedlander
Nov 20, 2004·Nature Reviews. Neuroscience·Graham L CollingridgeYu Tian Wang
Mar 31, 2005·Molecular and Cellular Neurosciences·Francesca BerettaMaria Passafaro
Sep 3, 2005·The EMBO Journal·Jonathan G Hanley, Jeremy M Henley
Oct 5, 2006·Journal of Neurochemistry·John Q WangLimin Mao
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Brian S Meldrum, Michael A Rogawski
Feb 17, 2007·Journal of Neurochemistry·Jonathan G Hanley
Dec 28, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kurt C MarsdenReed C Carroll
Aug 7, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yunlei YangQiang Zhou
Oct 24, 2008·Frontiers in Molecular Neuroscience·Jean-Marc Fritschy
Oct 24, 2008·Frontiers in Molecular Neuroscience·Verena Tretter, Stephen J Moss
Apr 17, 2009·Epilepsy Research·Poonam Nina BanerjeeW Allen Hauser
Apr 21, 2009·Current Opinion in Neurobiology·Ursula Koch, Anna K Magnusson
Aug 26, 2009·CNS & Neurological Disorders Drug Targets·Kari A JohnsonColleen M Niswender
Sep 1, 2009·RNA Biology·Andrew C Penn, Ingo H Greger

❮ Previous
Next ❯

Citations

Nov 11, 2020·Neuroscience and Biobehavioral Reviews·Salar VaseghiMohammad-Reza Zarrindast
Apr 1, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Jana Ruda-KucerovaYousef Tizabi
Apr 30, 2021·Neuropharmacology·Jeremy M HenleyKevin A Wilkinson

❮ Previous
Next ❯

Methods Mentioned

BETA
Antisense Oligonucleotide
pharmacotherapy

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Frontiers in Molecular Neuroscience
Gabrielle T Parkinson, Jonathan G Hanley
Expert Opinion on Investigational Drugs
Emilio RussoGiovambattista De Sarro
© 2021 Meta ULC. All rights reserved